KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Inventory: 2009-2025

Historic Inventory for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $1.4 billion.

  • Biomarin Pharmaceutical's Inventory rose 17.20% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 17.20%. This contributed to the annual value of $1.2 billion for FY2024, which is 11.33% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Inventory stood at $1.4 billion for Q3 2025, which was up 3.13% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Inventory registered a high of $1.4 billion during Q3 2025, and its lowest value of $711.0 million during Q2 2021.
  • For the 3-year period, Biomarin Pharmaceutical's Inventory averaged around $1.2 billion, with its median value being $1.2 billion (2024).
  • In the last 5 years, Biomarin Pharmaceutical's Inventory fell by 4.42% in 2021 and then climbed by 23.84% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Inventory (Quarterly) stood at $776.7 million in 2021, then rose by 15.12% to $894.1 million in 2022, then climbed by 23.83% to $1.1 billion in 2023, then rose by 11.33% to $1.2 billion in 2024, then increased by 17.20% to $1.4 billion in 2025.
  • Its Inventory stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.